213 related articles for article (PubMed ID: 16605283)
1. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
Sander B; Hayden FG; Gyldmark M; Garrison LP
Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
[TBL] [Abstract][Full Text] [Related]
2. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Talbird SE; Brogan AJ; Winiarski AP
Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
[TBL] [Abstract][Full Text] [Related]
3. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.
Sander B; Gyldmark M; Hayden FG; Morris J; Mueller E; Bergemann R
Eur J Health Econ; 2005 Sep; 6(3):244-52. PubMed ID: 15875227
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.
Vindt Holm M; Gyldmark M; Holme Hansen E
Pharm World Sci; 2004 Dec; 26(6):339-45. PubMed ID: 15683104
[TBL] [Abstract][Full Text] [Related]
5. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
[TBL] [Abstract][Full Text] [Related]
7. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Bellantonio S; Rose DN
Ann Intern Med; 2003 Sep; 139(5 Pt 1):321-9. PubMed ID: 12965940
[TBL] [Abstract][Full Text] [Related]
8. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
Talbird SE; Brogan AJ; Winiarski AP; Sander B
Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
Lee PY; Matchar DB; Clements DA; Huber J; Hamilton JD; Peterson ED
Ann Intern Med; 2002 Aug; 137(4):225-31. PubMed ID: 12186512
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
[TBL] [Abstract][Full Text] [Related]
13. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Shen K; Xiong T; Tan SC; Wu J
PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
[TBL] [Abstract][Full Text] [Related]
14. Antiviral agents for influenza: a comparison of cost-effectiveness data.
Lynd LD; Goeree R; O'Brien BJ
Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of newer treatment strategies for influenza.
Smith KJ; Roberts MS
Am J Med; 2002 Sep; 113(4):300-7. PubMed ID: 12361816
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit of stockpiling drugs for influenza pandemic.
Balicer RD; Huerta M; Davidovitch N; Grotto I
Emerg Infect Dis; 2005 Aug; 11(8):1280-2. PubMed ID: 16102319
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
Postma MJ; Novak A; Scheijbeler HW; Gyldmark M; van Genugten ML; Wilschut JC
Pharmacoeconomics; 2007; 25(6):497-509. PubMed ID: 17523754
[TBL] [Abstract][Full Text] [Related]
18. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
Hayden FG; Belshe R; Villanueva C; Lanno R; Hughes C; Small I; Dutkowski R; Ward P; Carr J
J Infect Dis; 2004 Feb; 189(3):440-9. PubMed ID: 14745701
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacoeconomic evaluation of oseltamivir as prophylaxis against influenza infection].
Sakamaki H; Ikeda S; Ikegami N
Yakugaku Zasshi; 2004 Apr; 124(4):207-16. PubMed ID: 15067184
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.
Wu DBC; Chaiyakunapruk N; Pratoomsoot C; Lee KKC; Chong HY; Nelson RE; Smith PF; Kirkpatrick CM; Kamal MA; Nieforth K; Dall G; Toovey S; Kong DCM; Kamauu A; Rayner CR
Epidemiol Infect; 2018 Mar; 146(4):496-507. PubMed ID: 29446343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
